Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.9%

1 terminated out of 17 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

12%

2 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed with results

Key Signals

94% success

Data Visualizations

Phase Distribution

17Total
P 1 (5)
P 2 (10)
P 3 (2)

Trial Status

Completed15
Withdrawn1
Terminated1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT00109759Phase 1WithdrawnPrimary

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

NCT00133146Phase 2CompletedPrimary

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

NCT00258635Phase 2CompletedPrimary

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

NCT00133159Phase 2CompletedPrimary

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

NCT00118612Phase 2CompletedPrimary

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

NCT00387478Phase 2TerminatedPrimary

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

NCT00414141Phase 3CompletedPrimary

Efficacy and Safety/Tolerability of Grass MATA MPL

NCT00104377Phase 2CompletedPrimary

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00113750Phase 2CompletedPrimary

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

NCT00110786Phase 2CompletedPrimary

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

NCT00241410Phase 1CompletedPrimary

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

NCT00116285Phase 1CompletedPrimary

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

NCT00325338Phase 2CompletedPrimary

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

NCT00107705Phase 1CompletedPrimary

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

NCT00423787Phase 3CompletedPrimary

Efficacy and Safety/Tolerability of Ragweed MATA MPL

NCT00118625Phase 2CompletedPrimary

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

NCT00104390Phase 1CompletedPrimary

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Showing all 17 trials

Research Network

Activity Timeline